So sánh hiệu quả và độ an toàn của rivaroxaban và heparin trọng lượng phân tử thấp ở bệnh nhân ung thư phổi người Trung Quốc có thuyên tắc phổi không nguy cơ cao
Tóm tắt
Dữ liệu hướng dẫn việc lựa chọn các chế độ điều trị chống đông khác nhau cho thuyên tắc tĩnh mạch (VTE) liên quan đến ung thư còn thiếu. Chúng tôi nhằm mục tiêu so sánh hiệu quả và độ an toàn của rivaroxaban và heparin trọng lượng phân tử thấp (LMWH) đối với thuyên tắc phổi không nguy cơ cao (PE) ở bệnh nhân ung thư phổi người Trung Quốc.
Bốn trăm bốn mươi sáu bệnh nhân ung thư phổi người Trung Quốc có thuyên tắc phổi không nguy cơ cao đã khởi đầu điều trị bằng rivaroxaban hoặc LMWH được xác định từ cơ sở dữ liệu Bệnh viện Trung Sơn từ năm 2016 đến 2020. Các kết quả chính là sự kiện tổng hợp của tái phát VTE hoặc chảy máu lớn, và tỷ lệ tử vong do mọi nguyên nhân. Các kết quả thứ cấp bao gồm tái phát VTE, chảy máu lớn và chảy máu không lớn có ý nghĩa lâm sàng (CRNMB). Phương pháp ghép cặp theo điểm có khả năng được sử dụng để cân bằng các biến gốc. Chúng tôi tiến hành phân tích độ nhạy bằng cách ổn định trọng số xác suất điều trị ngược và phân tích rủi ro cạnh tranh bằng mô hình rủi ro phân phối phụ của Fine và Gray.
Trong các nhóm được ghép cặp theo điểm, rivaroxaban tương đương với LMWH về các rủi ro của kết quả tổng hợp (tỷ lệ rủi ro (HR), 0.73; khoảng tin cậy (CI) 95%, 0.45–1.21;
Rivaroxaban có thể là một lựa chọn hứa hẹn thay thế cho LMWH trong điều trị khởi đầu thuyên tắc phổi không nguy cơ cao ở bệnh nhân ung thư phổi.
Từ khóa
Tài liệu tham khảo
Gervaso L, Dave H, Khorana AA. Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021;3(2):173–90. https://doi.org/10.1016/j.jaccao.2021.03.001.
Li Y, Shang Y, Wang W, Ning S, Chen H. Lung cancer and pulmonary embolism: what is the relationship? A review. J Cancer. 2018;9(17):3046. https://doi.org/10.7150/jca.26008.
Lee A, Parpia S, Julian J, Rickles F, Prins M, Levine M. Predictors of recurrent thrombosis and anticoagulant-related bleeding in patients with cancer. J Clin Oncol. 2009;27(15_suppl):9565. https://doi.org/10.1200/jco.2009.27.15_suppl.9565.
Qian X, Fu M, Zheng J, Zhou J, Zhou J. Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2021;11:680191-. https://doi.org/10.3389/fonc.2021.680191.
Steuer CE, Behera M, Kim S, Patel N, Chen Z, Pillai R, et al. Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. Lung Cancer. 2015;88(1):80–4. https://doi.org/10.1016/j.lungcan.2015.01.022.
Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, et al. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). Clin Lung Cancer. 2020;21(1):15–20. https://doi.org/10.1016/j.cllc.2019.06.012.
Moik F, Chan WE, Wiedemann S, Hoeller C, Tuchmann F, Aretin MB, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood. 2021;137(12):1669–78. https://doi.org/10.1182/blood.2020007878.
Roopkumar J, Poudel SK, Gervaso L, Reddy CA, Velcheti V, Pennell NA, et al. Risk of thromboembolism in patients with ALK-and EGFR-mutant lung cancer: a cohort study. J Thromb Haemost. 2021;19(3):822–9. https://doi.org/10.1111/jth.15215.
Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. https://doi.org/10.1093/eurheartj/ehz405.
Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–74. https://doi.org/10.1182/bloodadvances.2020003442.
Streiff MB, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J, et al. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(10):1181–201. https://doi.org/10.6004/jnccn.2021.0047.
Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, et al. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw. 2018;16(11):1289–303. https://doi.org/10.6004/jnccn.2018.0084.
Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA. 2015;314(7):677–86. https://doi.org/10.1001/jama.2015.9243.
Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–23. https://doi.org/10.1200/jco.2018.78.8034.
Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1(1):e37-46. https://doi.org/10.1016/s2352-3026(14)70018-3.
McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–21. https://doi.org/10.1111/jth.14662.
Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020;382(17):1599–607. https://doi.org/10.1056/NEJMoa1915103.
Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018;378(7):615–24. https://doi.org/10.1056/NEJMoa1711948.
Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020;38(5):496–520. https://doi.org/10.1200/jco.19.01461.
Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566–81. https://doi.org/10.1016/s1470-2045(19)30336-5.
Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97. https://doi.org/10.1056/NEJMoa1113572.
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808. https://doi.org/10.1056/NEJMoa1302507.
Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510. https://doi.org/10.1056/NEJMoa1007903.
Centers for Disease Control and Prevention International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Accessed 22 Dec 2020.
Centers for Disease Control and Prevention International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). Accessed 22 Dec 2020.
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4. https://doi.org/10.1111/j.1538-7836.2005.01204.x.
Yang D, Dalton JE, editors. A unified approach to measuring the effect size between two groups using SAS2012.
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–79. https://doi.org/10.1002/sim.6607.
Hill H, Robinson M, Lu L, Slaughter D, Amin A, Mileham K, et al. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy. Thromb Res. 2021;208:71–8. https://doi.org/10.1016/j.thromres.2021.10.014.
Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019;380(8):711–9. https://doi.org/10.1056/NEJMoa1814468.
Chen D-Y, Tseng C-N, Hsieh M-J, Lan W-C, Chuang C-K, Pang S-T, et al. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism. JAMA Netw Open. 2021;4(2):e2036304-e. https://doi.org/10.1001/jamanetworkopen.2020.36304.
Wysokinski WE, Houghton DE, Casanegra AI, Vlazny DT, Bott-Kitslaar DM, Froehling DA, et al. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Am J Hematol. 2019;94(11):1185–92. https://doi.org/10.1002/ajh.25604.
Costa OS, Kohn CG, Kuderer NM, Lyman GH, Bunz TJ, Coleman CI. Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism. Blood Adv. 2020;4(17):4045–51. https://doi.org/10.1182/bloodadvances.2020002242.
Riaz IB, Fuentes HE, Naqvi SAA, He H, Sipra QR, Tafur AJ, et al. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. Mayo Clin Proc. 2022;97(2):308–24. https://doi.org/10.1016/j.mayocp.2020.10.041.
Overvad TF, Larsen TB, Søgaard M, Albertsen IE, Ording AG, Noble S, et al. Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of clinical outcomes and patient perspectives. Expert Rev Cardiovasc Ther. 2020;18(11):791–800. https://doi.org/10.1080/14779072.2020.1822167.
Gu ZC, Yan YD, Yang SY, Shen L, Kong LC, Zhang C, et al. Direct versus conventional anticoagulants for treatment of cancer associated thrombosis: a pooled and interaction analysis between observational studies and randomized clinical trials. Ann Transl Med. 2020;8(4):95. https://doi.org/10.21037/atm.2019.12.152.
Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C, et al. Laboratory assessment of rivaroxaban: a review. Thromb J. 2013;11(1):11. https://doi.org/10.1186/1477-9560-11-11.
Jakowenko N, Nguyen S, Ruegger M, Dinh A, Salazar E, Donahue KR. Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system. Thromb Res. 2020;196:276–82. https://doi.org/10.1016/j.thromres.2020.09.002.
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019;380(8):720–8. https://doi.org/10.1056/NEJMoa1814630.
Lee JH, Hyun DG, Choi CM, Lee JC, Kim WS, Oh YM, et al. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer. Respiration. 2019;98(3):203–11. https://doi.org/10.1159/000499895.
Cha SI, Shin KM, Lim JK, Yoo SS, Lee SY, Lee J, et al. Pulmonary embolism concurrent with lung cancer and central emboli predict mortality in patients with lung cancer and pulmonary embolism. J Thorac Dis. 2018;10(1):262–72. https://doi.org/10.21037/jtd.2017.12.32.
Berghaus TM, Haeckel T, Behr W, Wehler M, von Scheidt W, Schwaiblmair M. Central thromboembolism is a possible predictor of right heart dysfunction in normotensive patients with acute pulmonary embolism. Thromb Res. 2010;126(3):e201–5. https://doi.org/10.1016/j.thromres.2010.06.009.
Kucher N, Printzen G, Doernhoefer T, Windecker S, Meier B, Hess OM. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation. 2003;107(12):1576–8. https://doi.org/10.1161/01.Cir.0000064898.51892.09.
Söhne M, Ten Wolde M, Boomsma F, Reitsma JB, Douketis JD, Büller HR. Brain natriuretic peptide in hemodynamically stable acute pulmonary embolism. J Thromb Haemost. 2006;4(3):552–6. https://doi.org/10.1111/j.1538-7836.2005.01752.x.
Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341(8844):507–11. https://doi.org/10.1016/0140-6736(93)90274-k.
Grifoni S, Olivotto I, Cecchini P, Pieralli F, Camaiti A, Santoro G, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation. 2000;101(24):2817–22. https://doi.org/10.1161/01.cir.101.24.2817.